On the MTD paradigm and optimal control for multi-drug cancer chemotherapy.
On the MTD paradigm and optimal control for multi-drug cancer chemotherapy.
复制标题
多药癌症化疗的 MTD 范式和最佳控制。
DOI：
--
复制
发表时间：
2013
期刊：
影响因子：
--
通讯作者：
S. Dehkordi
中科院分区：
文献类型：
--
作者：
U. Ledzewicz;H. Schättler;Mostafa Reisi Gahrooi;S. Dehkordi
在标准的化疗方案中，药物以最大耐受量(MTD)给药，其间有休息时间。在本文中，我们简要讨论了这种治疗方法背后的基本原理，并以使用细胞毒性和细胞抑制剂的多药癌症化疗为例，表明这些类型的方案在最小化肿瘤细胞数量(在治疗结束时和中间时间服用)和总剂量的加权平均意义上是最优的，如果假设肿瘤由化疗敏感细胞组成的同质群体。用二室线性模型模拟药物的药代动力学方程。
In standard chemotherapy protocols, drugs are given at maximum tolerated doses (MTD) with rest periods in between. In this paper, we briey discuss the rationale behind this therapy approach and, using as example multidrug cancer chemotherapy with a cytotoxic and cytostatic agent, show that these types of protocols are optimal in the sense of minimizing a weighted average of the number of tumor cells (taken both at the end of therapy and at intermediate times) and the total dose given if it is assumed that the tumor consists of a homogeneous population of chemotherapeutically sensitive cells. A 2-compartment linear model is used to model the pharmacokinetic equations for the drugs.